These pharmacokinetic profiles validate the feasibility of repurposing these drugs for H. pylori–associated gastric cancer, as their favorable drug-likeness and bioavailability support their potential to effectively target hub genes like CXCL1, CCL20, and IL12B, which drive inflammation and immune dysregulation. This evidence concerns the gene CCL20 and gastric cancer.